We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.84%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.85B
AUM Growth
+$135M
Cap. Flow
-$725M
Cap. Flow %
-39.12%
Top 10 Hldgs %
58.55%
Holding
374
New
79
Increased
68
Reduced
92
Closed
116

Top Buys

Rank Stock Value
1
BIOA
BioAmber Inc.
BIOA
+$5.55M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.2M
3
OTIC
Otonomy, Inc.
OTIC
+$3.92M
4
BLRX
BioLineRX
BLRX
+$3.37M
5
SLS icon
SELLAS Life Sciences
SLS
+$2.7M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$62.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$59.7M
3
AMGN icon
Amgen
AMGN
+$35.8M
4
LLY icon
Eli Lilly
LLY
+$15.7M
5
BIIB icon
Biogen
BIIB
+$5.67M

Sector Composition

Rank Sector Weight
1 Healthcare 6.29%
2 Materials 0.25%
3 Financials 0.16%
4 Consumer Staples 0.04%
5 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDCO
351
PUT
DELISTED
Medicines Co
MDCO
– –
-1,172
Closed -$3.98M
CLRBW
352
DELISTED
Cellectar Biosciences, Inc.
CLRBW
– –
-201,889
Closed -$85K
HZNP
353
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-5,962
Closed -$9.65M
HZNP
354
PUT
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-2,791
Closed -$4.52M
ESRX
355
CALL
DELISTED
Express Scripts Holding Company
ESRX
– –
-2,897
Closed -$19.9M
ESRX
356
DELISTED
Express Scripts Holding Company
ESRX
– –
-23,494
Closed -$1.62M
ESRX
357
PUT
DELISTED
Express Scripts Holding Company
ESRX
– –
-1,191
Closed -$8.19M
ANTH
358
CALL
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
– –
-123
Closed -$64K
JUNO
359
CALL
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-103
Closed -$194K
DXTR
360
DELISTED
Dextera Surgical Inc.
DXTR
– –
-397,863
Closed -$382K
OCRX
361
DELISTED
Ocera Therapeutics, Inc.
OCRX
– –
-328,632
Closed -$690K
CEMP
362
DELISTED
Cempra, Inc.
CEMP
– –
-43,121
Closed -$121K
KITE
363
CALL
DELISTED
Kite Pharma, Inc.
KITE
– –
-1,171
Closed -$5.25M
ROSG
364
DELISTED
Rosetta Genomics Ltd.
ROSG
– –
-49,278
Closed -$248K
WGBS
365
DELISTED
WaferGen Bio-systems, Inc.
WGBS
– –
-358,535
Closed -$1.77M
ACUR
366
DELISTED
Acura Pharmaceuticals
ACUR
– –
-103,444
Closed -$79K
SGYPW
367
CALL
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
– –
-7,536
Closed -$4.59M
AST
368
CALL
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
– –
-200
Closed -$92K
NDRM
369
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-23,033
Closed -$511K
LJPC
370
DELISTED
La Jolla Pharmaceutical Company
LJPC
– –
-210,978
Closed -$5.39M
LJPC
371
PUT
DELISTED
La Jolla Pharmaceutical Company
LJPC
– –
-336
Closed -$589K
ETRM
372
DELISTED
EnteroMedics Inc.
ETRM
– –
-33,387
Closed -$67K
GNVC
373
DELISTED
GenVec, Inc.
GNVC
– –
-120,544
Closed -$387K
11 12 13 14
15

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q1 2017 Portfolio in Review

As of Q1 2017, Sabby Management held 374 positions worth $1.85B, up 7.8% from $1.72B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management withdrew a net $725M in Q1 2017, closing 116 positions and reducing 92 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $62.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 6.3% of assets, down from 18% a quarter earlier, followed by Materials and Financials.

Against the trend, Sabby Management opened a new position in BioAmber Inc. worth $3.39M.

  • Sabby Management's largest Q1 2017 buy was BioAmber Inc.: 1,460,859 shares worth $3.39M.
  • Sabby Management added most to Otonomy, Inc. in Q1 2017, an estimated $3.92M increase.
  • Sabby Management's biggest Q1 2017 reduction was Amgen, cutting an estimated $35.8M.
  • Sabby Management fully exited Sarepta Therapeutics in Q1 2017, selling an estimated $62.4M.
  • Sabby Management's ten largest holdings make up 59% of its $1.85B portfolio in Q1 2017.
  • Sabby Management opened 79 new positions and closed 116 in Q1 2017.
  • Sabby Management's portfolio value rose 7.8% quarter-over-quarter to $1.85B.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.